Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

New Research Reports For GE, McDonald's & GSK

Published 09/26/2016, 11:45 PM
Updated 07/09/2023, 06:31 AM

Tuesday, September 27, 2016

Stocks started the Tuesday session modestly in the green after two down sessions, with many seeing the tightening presidential election as adding to market uncertainty. Oil, gold, the U.S. dollar and the 10-year Treasury bond yield lost ground in the morning, with the oil pullback likely indicating the market's skepticism of OPEC's ability to come out with anything meaningful in tomorrow's meeting in Algiers. On the data front, this morning's July Case-Shiller home price index showed +5.1% increase, which follows the prior-month's +5% gain.

We are featuring 16 research reports on major stocks in today's Research Daily, including General Electric (NYSE:GE), GlaxoSmithKline (GSK) and McDonald’s (MCD).

Buy rated General Electric shares have lagged the market this year on concerns about the conglomerate's order backlog and continued weakness in the energy end-market. This issue notwithstanding, the company has done an excellent job of its plan to reduce its exposure to finance and get back to its industrial and engineering roots. To that end, it is enjoying strong momentum in the power and aviation end markets, partly offset by continued weakness in the energy space. A track record of returning excess cash to shareholders through buybacks and dividends (dividend yields an attractive 3.1%) are some of the other positives in the GE story. (You can read the full research report on GE here>>)

GlaxoSmithKline shares have gained more than 7% year-to-date, outperforming many of its large-cap pharma peers. The buy rated stock is positioned to deliver strong core earnings growth on the back of performance momentum in its new products as well as those acquired from Novartis. These should help support revenues and ease the impact of the loss of Advair sales. Glaxo’s efforts to develop its pipeline are also encouraging. Moreover, steps to increase cost efficiency and its outlook for the next five years bode well. You can read the full research report on GlaxoSmithKline here>>)

McDonald’s shares have been weak lately on soft industry trends, macroeconomic concerns in various parts of the world along with negative currency translation issues. However, the analyst likes the manner in which McDonald’s has turned itself around in the domestic market like menu innovation, introduction of value meals, efficient marketing and promotions, and improved service. (You can read the full research report on McDonald’s here>>)

Other noteworthy reports we are featuring today include Caterpillar (NYSE:CAT), 3M (MMM) and Medtronic (NYSE:MDT).

Free Access: All Zacks Research Reports
Starting today, you are invited to download in-depth analysis reports covering more than 1,000 of the most widely followed stocks. Valued at $25 each, they are yours to consult over the next 30 days absolutely free. They feature sensitive Zacks Rank information on each stock that you won't find anywhere else. See the reports free >>

You can find all of today's stock research reports here>>

Sheraz Mian

Director of Research

Note: If you want an email notification each time Sheraz publishes a new article, please click here>>

Featured Reports

Sunoco Logistics (SXL) to Acquire Permian Assets for $760M

According to the covering analyst, Sunoco Logistics' acquisition of Vitol's crude oil unit in Permian Basin will expand its footprint in a region that is profitable even at current low prices.

AAR Corp.'s (AIR) Q1 Earnings & Sales Beat Estimates, Up Y/Y

The Zacks analyst upgraded AAR Corp to Strong Buy buoyed by its better-than-expected fiscal first 2017 quarter results.

Magna International (MGA) to Buy Automotive Supplier BOCO

The acquisition of BOCO is expected to strengthen Magna International's product portfolio, boost its revenues and enhance its engineering capabilities in key regions, per the Zacks analyst.

Akamai (AKAM) Takes Krebs' Site Off Server After Cyberattack

The Zacks analyst believes that despite the recent cyberattack, Akamai's leading position in the CDN space along with growing cloud demand augur well.

Torchmark's (NYSE:TMK) Capital Management Continues to Impress

The Zacks analyst believes that Torchmark's robust capital management strategy will enable the company to return more value to its shareholders.

Medtronic (MDT) Thrives on Innovations, Synergies amid Woes

The Zacks analyst thinks the recent Neurosurgery product launch is a part of the effort to capture the vast market of brain therapies.

Analog Devices (ADI) Hurt by Weakness in the Consumer Market

The Zacks analyst believes that strength in the industrial, auto and communication markets is largely offset by significant weakness in the consumer business.

New Upgrades

Southern Company's (NYSE:SO) AGL Buy Widens Customer Base

The Zacks analyst believes that Southern Company's $12 billion acquisition of AGL Resources (NYSE:GAS) has significantly increased its customer base and is expected to help generate more revenues.

Caterpillar (CAT) Aug Sales Show Improvement in Asia Pacific

Caterpillar's Aug sales reveal a steady improvement in Asia Pacific construction. The covering analyst thinks this development along with its improved restructuring actions, bodes well for the behemoth.

Edison (EIX) Up on Strong Portfolio, Solid Cash Flow Reserve

The Zacks analyst thinks Edison's strong portfolio of regulated utility assets allows it to present a lower risk profile. Its solid financial position is backed by strong cash generation capacity.

New Downgrades

Vertex's (VRTX) Orkambi 2016 Guidance Below Expectations

The Zacks analyst believes Vertex's Orkambi guidance for 2016 is short of expectations due to slower than expected launch in Germany. Also worrying is its dependence on the CF franchise for growth.

3M (MMM) Plagued by Various Macroeconomic Risks

A sustained strength in the U.S. dollar will likely continue to negatively impact the earnings in the short-term. In addition, the company is susceptible to high commodity price risks.

Cost Pressure, Fee Waivers Weigh on T. Rowe Price (TROW)

The Zacks analyst thinks T. Rowe Price's planned initiatives will weigh on expense base. Also, amid the low rate environment, fee waivers in its money market mutual funds hurts revenue growth.



3M CO (MMM): Free Stock Analysis Report

MEDTRONIC (MDT): Free Stock Analysis Report

MCDONALDS CORP (MCD): Free Stock Analysis Report

GLAXOSMITHKLINE (GSK): Free Stock Analysis Report

GENL ELECTRIC (GE): Free Stock Analysis Report

CATERPILLAR INC (CAT): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.